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any efficacy measures are used to assess change
and outcome in antidepressant trials, and they
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Objectives: This post hoc analysis compared
how patients and physicians estimate disease se-
verity and global improvement during 8 weeks
of treatment for major depressive disorder (MDD)
with associated nonspecific pain. In addition, pre-
dictors of pain and depression were identified.
Method: Data were derived from a double-
blind, placebo-controlled, multicenter, European
study (conducted from May 2005 to May 2006)
in adult outpatients with MDD (DSM-IV criteria)
and moderate pain not attributable to a diagnosed
organic pain syndrome (Brief Pain Inventory-
Short Form [BPI-SF] average pain score ≥ 3).
Patients were randomly assigned to duloxetine
60 mg/day or placebo and treated for 8 weeks.
Physicians were asked to rate severity of depres-
sion by using the Montgomery-Asberg Depres-
sion Rating Scale (MADRS) and the Clinical
Global Impressions-Severity of Illness (CGI-S)
and CGI-Improvement (CGI-I) scales. Patients
were asked to assess pain using the BPI-SF, psy-
chological symptomatology (9 domains including
depression) with the Symptom Checklist-90-
Revised (SCL-90-R), and overall improvement
with the Patient Global Impression of Improve-
ment (PGI-I). Multivariate linear regressions
were performed as post hoc analyses to identify
predictors of disease assessment at baseline and
at the end of the study using a last-observation-
carried-forward approach.
Results: All SCL-90-R domains improved
during the 8 weeks of treatment. At baseline, the
MADRS was associated only with the SCL-90-R
obsessive-compulsive score, while the SCL-90-R
depression score was associated with the BPI-SF
average pain score and with many SCL-90-R
subscores. The global impression of improvement
was rated higher by the physicians than by the
patients. At the end of the study, CGI-I was sig-
nificantly associated with a decrease in depres-
sion severity (MADRS; p < .0001), younger
age (p = .0005), and a decrease of the SCL-90-R
interpersonal sensitivity score (p = .0359), but not
with BPI-SF average pain. In contrast, patient-
rated PGI-I was significantly associated with the
SCL-90-R depressive domain (p < .0001), BPI-SF
average pain (p = .0003), and the SCL-90-R
anxiety domain (p = .0041) scores.
Conclusion: In patients with MDD associated
with at least moderate nonspecific pain, physi-
M
cians consider mainly the change in depressive
symptoms as measured by MADRS in their CGI-I
ratings, while patients also consider pain, depres-
sion, and anxiety in their PGI-I ratings. When
treating depression and assessing treatment out-
come, a broad spectrum of symptoms needs to be
monitored.
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differ in format and in content. The primary endpoint is
usually defined as a change on a symptom scale reflecting
the symptoms of the primary diagnosis.
A first distinction can be made between observer-rated
instruments, such as the Hamilton Rating Scale for De-
pression (HAM-D) and the Montgomery-Asberg Depres-
sion Rating Scale (MADRS), and self-rated instruments,
such as the Beck Depression Inventory (BDI) and the
Symptom Checklist-90-Revised (SCL-90-R).
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A second distinction can be made between instru-
ments assessing syndromal symptomatology (HAM-D,
MADRS, BDI, and SCL-90-R) and instruments assessing
overall impression of clinical status and/or change, the
latter generally being very short. The Clinical Global Im-
pressions scale (CGI)1 is such an “overall” assessment
tool that generally shows good sensitivity to change, and
its use has become so widespread that it is now a standard
outcome measure in psychopharmacology trials. Since
the term global gives the impression of comprehensive-
ness, this judgment may also be expected to be more rep-
resentative for the actually observed and clinically rel-
evant status or change.2 But it has also been suggested that
the global impression is an enigmatic and wavering term
with poor psychometric validation and with semantic
problems (for example, quality gaps with regard to inten-
sity rating and no precise definitions of different catego-
ries) and logical problems (for example, a “moderately
ill” patient cannot manifest “very much” improvement).3
The first CGI item assesses the clinician’s impression
of the patient’s current illness severity (CGI-S) on a uni-
polar scale of 1 (not at all ill) to 7 (among the most ex-
tremely ill). The judgment is restricted within the range of
the specific population under study.1 The next 2 items of
the CGI address the patient’s improvement from baseline,
one rated by the clinician (Clinical Global Impressions-
Improvement [CGI-I] scale) and the other by the patient
(Patient Global Impression of Improvement [PGI-I]).
Both items show a bipolar scaling from 1 (very much im-
proved) to 7 (very much worse). The correlation between
the PGI-I (patient global impression of change) and the
CGI-I (clinical global impression of change) has been
poorly investigated.
The term global does remain somewhat elusive and
it is unclear which aspects of an individual’s functioning
actually determine such ratings. Changes in symptoms
scores have been shown to account for 38% to 40% of the
variance in CGI-S and 26% to 46% of the variance in
CGI-I.4 The authors of this study suggest that other factors
related to illness, such as appraisal of an individual’s dis-
tress, discomfort, and impairment, may account for the
remaining variance in CGI ratings. In a study evaluating
the CGI scale among individuals with social anxiety dis-
order, it was indeed shown that CGI-S and CGI-I were not
only strongly correlated with observer- or self-rated se-
verity of anxious symptoms but also with observer- or
self-rated severity of comorbid depressive symptoms.5
The latter finding is important since it shows a limitation
of using just 1 symptom scale for assessing treatment out-
come. Indeed, the main symptom scale used usually re-
flects the symptoms of the main diagnosis and illustrates
one of the weaknesses of the currently used diagnostic
classification systems such as the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-
IV): comorbid disorders are generally well assessed but
comorbid symptoms are not. Assessing outcome with
only 1 symptom scale (reflecting the symptom cluster and
severity of the primary “diagnosis”) could hence result
in a “tunnel perspective” of the treating physician: once
a physician makes a primary diagnosis of major de-
pressive episode on the basis of the variety of symptoms
a patient presents with, it is not well documented wheth-
er frequently comorbid symptoms (anxiety symptoms,
obsessive-compulsive symptoms, interpersonal sensitiv-
ity, somatic nonpainful symptoms, and somatic painful
symptoms) are further taken into account when assessing
change during treatment.6,7 From this perspective, the
HAM-D covers a broader set of symptoms than the
MADRS, with the former scale also focusing on anxiety
and somatic symptoms and the latter mainly focusing on
depressive symptoms.8 The study by Zaider et al.5 sug-
gests that more data are needed to understand what
symptom changes contribute to the impression of global
change and whether the same symptom changes pre-
dict the physician’s perspective (CGI-I) as well as the
patient’s perspective (PGI-I).
This article aims to provide answers to these issues,
including (1) the relation between different observer- and
self-rated symptom scales (depressive and other comor-
bid psychological and somatic symptoms) in a population
of outpatients with depression and pain, at baseline and
during treatment; (2) the relation between global impres-
sion scales (CGI-I for the physician’s perspective and
PGI-I for the patient’s perspective); and (3) the investiga-
tion of what symptom changes predict the CGI, the PGI,
and the difference of both assessments.
METHOD
Study Design
The data for the current post hoc analyses were
derived from a randomized, double-blind, placebo-
controlled, parallel-group study conducted from May
2005 to May 2006 in 5 European countries (Belgium,
Finland, France, Germany, and Slovakia) in outpatients
with major depressive disorder (MDD) and at least mod-
erate pain.9 The study duration was 10 weeks consisting
of an 8-week treatment period and a 2-week tapering
period. The treatments were placebo or duloxetine 60
mg/day, escalated from 30 mg/day after the first study
week, followed by tapering after 7 weeks of treatment at
60 mg/day to 30 mg/day for 2 weeks. Eli Lilly and Com-
pany and Boehringer Ingelheim GmbH sponsored this
study (ClinicalTrials.gov registration #NCT00191919).
Patients
A total of 321 adult male or female outpatients (du-
loxetine, N = 156; placebo, N = 165) with a diagnosis
of MDD as defined by the DSM-IV10 were included.
The diagnosis was confirmed by the Mini-International
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Neuropsychiatric Interview (MINI, version 5.0.0), a
standardized diagnostic interview based on DSM-IV cri-
teria.11 At baseline, all patients had a depression severity
(MADRS) total score of ≥ 20 and at least a moderate
pain (Brief Pain Inventory-Short Form [BPI-SF]) score
of ≥ 3 for the “24-hour average pain” item.12 At screen-
ing and at baseline, all patients had to be at least “moder-
ately ill” as measured by a score of ≥ 4 on the CGI-S
scale. The patients were devoid of any organic pain syn-
drome based on present and past medical history. Fur-
thermore, patients must have had 1 previous depressive
episode in their past medical history. Exclusion criteria
and reasons for study exclusion have been discussed by
Brecht et al.9 All patients signed an informed consent ap-
proved by the institutional ethical review board at each
investigational site before their enrollment. The study
was conducted in accordance with the Declaration of
Helsinki.
Outcome Measures
Physician-rated scales. Depression severity was as-
sessed with the MADRS scale13 at screening (visit 1) and
at all visits. The scale includes 10 items that assess the
core symptoms of depression. The items are scored from
0 to 6 with a maximum total score of 60. Reduction in
score is a measure of symptom improvement.
The physicians used the CGI-S and CGI-I scales to
evaluate the global disease severity and global improve-
ment of patients.1 The severity of the disease was as-
sessed by the same evaluator throughout the study using
the CGI-S item on a scale of 1 (normal) to 7 (most ex-
tremely ill) from screening to week 8; the CGI-I was
used to assess the patient’s “global change” on a scale
of 1 (very much improved) to 7 (very much worse) from
week 1 through week 8. For the CGI-I and the PGI-I,
the following categorizations were made: “improved”
(scores 1 and 2), “stable” (scores 3, 4, and 5), or “wors-
ened” (scores 6 and 7).
Patient-rated scales. The SCL-90-R was designed
to characterize the global symptomatology and psycho-
logical distress of psychiatric outpatients14–16 and gives 9
domains, including somatization, obsessive-compulsive
symptomatology, interpersonal sensitivity, depression,
anxiety, anger/hostility, phobic anxiety, paranoid ide-
ation, and psychoticism. The SCL-90-R was adminis-
tered from baseline through week 8.
The BPI-SF12 is a patient-rated instrument that mea-
sures pain intensity as well as other pain aspects on an
11-point Likert scale ranging from 0 (no pain or interfer-
ence) to 10 (most severe pain or complete interference).
Item 5 (average pain in the last 24 hours) of the BPI-SF
was assessed at screening, baseline, and all other study
visits. The BPI-SF interference questions were included
to determine how much patients were limited by pain in
their daily functioning (via 7 items: general activity,
mood, walking, normal work, relations with others, sleep,
and enjoyment of life).
The patients self-rated their “global change,” ranging
from 1 (very much better) to 7 (very much worse) using
the PGI-I scale at weeks 3 through 8.
Statistical Analyses
All the analyses were conducted on the full analysis set
(all patients who have received at least 1 dose of study
medication and who have at least a baseline and a post-
baseline value available for efficacy evaluation).
Cochran-Mantel-Haenszel tests adjusted on centers
were performed to compare percentage of responders on
CGI-I and PGI-I at endpoint (using a last-observation-
carried-forward [LOCF] approach).
Multivariate linear regressions were performed as post
hoc analyses to identify predictors of disease assessment at
baseline and at the end of the study (LOCF). Models were
fit to raw data with no stepwise approach.
The evolution of SCL-90-R variables between the treat-
ment groups was assessed with a maximum likelihood–
based, mixed-effects model repeated-measures analysis
using all the observations at each postbaseline visit over 8
weeks of double-blind treatment. The model included the
fixed categorical effects of treatment, center, visit, and
treatment-by-visit interaction, as well as the continuous
fixed covariates of baseline score and baseline score-by-
visit interaction. The covariance structure to model the
within-patient errors was unstructured; the Kenward-
Roger method was used to estimate denominator degrees
of freedom; and type III sum of squares for the least
squares mean was used.
RESULTS
Relation Between Observer-Rated and
Self-Rated Symptom Scales (depressive and
other comorbid psychological and somatic symptoms)
Pain severity, interference of pain with functioning,
and psychological variables from baseline to endpoint.
The baseline and endpoint (LOCF) scores for all observer-
rated and self-rated variables, including BPI-SF subscales,
MADRS, and SCL-90-R domains, are presented in Table
1. Unadjusted means and standard error (SE) of the mean
are displayed. The significant superior effect of duloxetine
over placebo in reducing MADRS and BPI-SF scores has
been reported previously.9
Observer-rated versus self-rated depression sever-
ity, SCL-90-R domains, and average pain severity/
interference with functioning. Since the study sample
were outpatients with MDD and moderate pain, the rela-
tionship between different symptom clusters was further
investigated.
Table 2 shows the significant associations of the dif-
ferent SCL-90-R domains (excluding depressive symp-
Patient-Rated vs. Physician-Rated Outcomes in MDD
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tomatology) with the observer-rated depression severity
(MADRS) at baseline and at week 8 (linear-regression
models). At baseline, only a higher SCL-90-R obsessive-
compulsive symptom score was significantly associated
with a higher baseline MADRS score. At week 8, the
MADRS was significantly associated with BPI-SF aver-
age pain and with more psychopathological dimensions:
positively with obsessive-compulsive symptomatology,
interpersonal sensitivity, and anxiety, and negatively with
phobic anxiety and paranoid ideation.
Table 3 shows the significant associations of the differ-
ent SCL-90-R domains (excluding depressive symptom-
atology) with the self-rated depression severity (SCL-90-R
depressive domain) at baseline and at week 8. At baseline
Table 1. Baseline and Week 8 Scores for All Observer-Rated and Self-Rated Variablesa
Duloxetine Placebo
Variable Baseline Week 8 Baseline Week 8
BPI-SF average pain, mean (SE) 5.78 (0.13) 3.43 (0.21) 5.63 (0.12) 4.09 (0.19)
BPI-SF interference, mean (SE) 5.58 (0.15) 2.72 (0.20) 5.47 (0.14) 3.79 (0.19)
General activity 6.20 (0.17) 3.28 (0.23) 5.93 (0.15) 4.32 (0.22)
Mood 6.42 (0.17) 3.00 (0.23) 6.19 (0.16) 4.17 (0.22)
Walking ability 4.03 (0.23) 2.09 (0.22) 4.08 (0.22) 2.99 (0.22)
Work 5.69 (0.19) 2.85 (0.22) 5.53 (0.15) 3.97 (0.21)
Relations with people 4.88 (0.21) 2.11 (0.21) 4.78 (0.19) 3.11 (0.21)
Sleep 5.66 (2.20) 2.91 (0.24) 5.63 (0.19) 3.91 (0.23)
Enjoyment of life 6.18 (0.20) 2.79 (0.23) 6.14 (0.17) 4.08 (0.23)
MADRS, mean (SE) 29.91 (0.37) 14.78 (0.85) 29.30 (0.35) 19.06 (0.74)
SCL-90-R, mean (SE) (GSI) 1.46 (0.05) 0.81 (0.06) 1.51 (0.05) 1.08 (0.06)
Somatization 1.72 (0.76) 0.99 (0.82) 1.83 (0.70) 1.31 (0.83)
Obsessive-compulsive symptoms 1.80 (0.85) 1.03 (0.91) 1.83 (0.76) 1.34 (0.90)
Interpersonal sensitivity 1.35 (0.86) 0.71 (0.81) 1.41 (0.89) 0.97 (0.89)
Depressive symptoms 2.13 (0.76) 1.14 (0.99) 2.17 (0.72) 1.51 (0.91)
Anxiety symptoms 1.49 (0.85) 0.81 (0.84) 1.59 (0.78) 1.10 (0.89)
Anger/hostility 0.88 (0.82) 0.47 (0.66) 0.99 (0.93) 0.71 (0.89)
Phobic anxiety 0.83 (0.46) 0.46 (0.72) 0.82 (0.79) 0.63 (0.79)
Paranoid ideation 1.14 (0.96) 0.64 (0.82) 1.12 (0.90) 0.80 (0.88)
Psychoticism 0.84 (0.67) 0.48 (0.64) 0.87 (0.70) 0.66 (0.75)
CGI-S, n (%)b
Moderate 130 (83.3) 78 (50.0) 134 (83.2) 104 (65.4)
Severe 26 (16.7) 6 (3.9) 27 (16.8) 11 (6.9)
aUnadjusted means and standard errors (SE) of the mean at baseline and at visit 8 (using last-observation-
carried-forward imputation method) are displayed in this table.
bN = 156 duloxetine, N = 161 placebo (baseline); N = 156 duloxetine, N = 159 placebo (endpoint).
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form, CGI-S = Clinical Global Impressions-Severity
of Illness scale, GSI = general severity index, MADRS = Montgomery-Asberg Depression Rating Scale,
SCL-90-R = Symptom Checklist-90-Revised.
Table 2. Regression Analysis Showing the Significant Predictors of the MADRS at Baseline and at Week 8a,b
SCL-90-R SCL-90-R SCL-90-R SCL-90-R SCL-90-R
MADRS BPI-SF Average Pain Obsessive-Compulsive  Interpersonal Sensitivity Anxiety Phobic Anxiety Paranoid Ideation
Baseline … 3.69 … … … …
Week 8 4.06 3.92 2.57 2.64 –3.79 –2.67
aThe t values from the linear multivariate regression model are displayed in this table; only t values that are significant at p ≤ .05 are listed.
bCovariates taken into account were the following: all the SCL-90-R subdomains except SCL-90-R depressive domain, number of pains, and BPI-SF
average pain.
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form, MADRS = Montgomery-Asberg Depression Rating Scale, SCL-90-R = Symptom
Checklist-90-Revised).
Symbol: … = not significant.
Table 3. Regression Analysis Showing the Significant Predictors of SCL-90-R Depression at Baseline and at Week 8a,b
BPI-SF SCL-90-R SCL-90-R SCL-90-R SCL-90-R SCL-90-R
SCL-90-R Depression Average Pain Obsessive-Compulsive Interpersonal Sensitivity Anxiety Phobic Anxiety Paranoid Ideation
Baseline 2.40 6.06 5.18 5.10 –3.05 …
Week 8 3.45 7.55 7.13 3.97 –4.09 –4.05
aThe t values from the linear multivariate regression model are displayed in this table; only t values that are significant at p ≤ .05 are listed.
bCovariates taken into account were the following: all the SCL-90-R domains except SCL-90-R depressive domain, number of pains, and BPI-SF
average pain.
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form, SCL-90-R = Symptom Checklist-90-Revised,
Symbol: … = not significant.
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as well as at week 8, a higher BPI-SF average pain
score, a higher SCL-90-R obsessive-compulsive symp-
tom score, a higher SCL-90-R interpersonal sensitivity
score, a higher SCL-90-R anxiety score, and a lower SCL-
90-R phobic anxiety score, as well as a lower SCL-90-R
paranoid ideation score (but only at week 8), were signifi-
cantly associated with the SCL-90-R depressive score.
Table 4 shows the significant associations of the differ-
ent SCL-90-R domains with BPI-SF average pain and of
BPI-SF interference (interference of pain with function-
ing) at baseline and at week 8. Higher baseline SCL-90-R
depressive domain score, a lower baseline interpersonal
sensitivity domain score, and a lower baseline phobic
anxiety domain score were associated with a higher base-
line average pain severity. A higher endpoint SCL-90-R
depressive domain score, higher endpoint SCL-90-R
somatization score, higher endpoint SCL-90-R anxiety
score, and being female were associated with a higher
average pain severity at endpoint.
A higher baseline average pain severity, higher base-
line SCL-90-R somatization, lower baseline SCL-90-R
interpersonal sensitivity, higher baseline SCL-90-R de-
pression, lower baseline SCL-90-R anxiety, and older age
were associated with a higher interference of pain with
functioning (average of the 7 interference of pain with
functioning items). A higher endpoint pain severity,
higher endpoint SCL-90-R somatization, higher endpoint
SCL-90-R depression, and lower endpoint SCL-90-R
paranoid symptomatology were associated with a higher
endpoint interference of pain with functioning.
Clinical Global Impression of Improvement
Versus Patient Global Impression of Improvement
The CGI-I scores showed that from the physician’s
perspective, 63% of the patients on treatment with dulox-
etine and 42% of the patients taking placebo “improved.”
On the other hand, the PGI-I scores showed that from the
patient’s perspective, 51% of the patients on treatment
with duloxetine and 31% of the patients taking placebo
“improved” (Figures 1A and 1B).
There was a concordance between CGI-I and PGI-I in
161 patients (54%), but, in 113 patients (35%), the physi-
cian concluded a greater improvement than the patient,
while in 32 patients (11%), the physician concluded a
Table 4. Significant (p values) Predictors of BPI-SF Average Pain and of BPI-SF Interference of Pain With Functioning at
Baseline and at Week 8a
SCL-90-R SCL-90-R SCL-90-R
BPI-SF SCL-90-R Interpersonal SCL-90-R SCL-90-R Phobic Paranoid
BPI-SF Average Pain Somatization Sensitivity Depression Anxiety Anxiety Ideation Age Sex
Average pain at baselineb … … .0018 .0158 … .0194 … … …
Average pain at week 8c … .001 … .0004 .009 … … … .0008
Interference at baselined .0001 .0005 .042 .0001 … .0305 … .0056 …
Interference at week 8d .0001 .0001 … .0001 … … .0368 … …
aOnly p values that are significant at ≤ .05 are listed.
bCovariates taken into account at baseline were SCL-90-R domains 2 through 9, gender, and age.
cCovariates taken into account at week 8 were SCL-90-R domains 1 through 9, gender, and age.
dBPI-SF interference is the sum of all interference sub-items (sum of the 7 items); covariates taken into account at baseline and week 8 were number
of pains, BPI-SF average pain, SCL-90-R domains 1 through 9, gender, and age.
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form, SCL-90-R = Symptom Checklist-90-Revised.
Symbol: … = not significant.
Figure 1. Clinical Global Impression of Improvement (A) Versus Patient Global Impression of Improvement (B)
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aCochran-Mantel-Haenszel test stratified by study center (full analysis set, last observation carried forward).
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smaller improvement than the patient. The concordance
was found in as many patients taking duloxetine as pla-
cebo (54% and 54%), but the discrepancy of improvement
showed some numerical differences between the treat-
ment groups. Physicians concluded there was a greater
improvement than did the patients in 38% of patients tak-
ing duloxetine and in 33% of patients taking placebo.
Physicians concluded a smaller improvement than the pa-
tients in 7% of patients taking duloxetine and in 13% of
patients taking placebo.
Predictors of Global Assessment of Improvement
Regression analyses were performed in order to inves-
tigate what symptom clusters predicted “improvement” as
assessed by the physicians versus the patients (Table 5).
At study endpoint, a higher CGI-I was significantly
predicted by a more pronounced decrease in depression
severity (MADRS), younger age, and a decrease in SCL-
90-R interpersonal sensitivity, but was not significantly
predicted by BPI-SF average pain. In contrast, a higher
PGI-I was predicted by a more pronounced decrease in
SCL-90-R depression, a more pronounced decrease in
BPI-SF average pain, and a more pronounced decrease
in SCL-90-R anxiety.
Finally, a regression analysis was performed to deter-
mine whether the difference between CGI-I and PGI-I
could be predicted by the sociodemographic, pain, and
psychological variables (Table 6). A relatively higher im-
pression of improvement by the physician than by the pa-
tient was predicted by a greater decrease in MADRS, a
greater decrease in interference of pain with relations with
people, and a greater decrease in SCL-90-R interpersonal
sensitivity, as well as by a smaller decrease in SCL-90-R
depression and a smaller decrease in BPI-SF average
pain.
DISCUSSION
Patients with depression associated with moderate
pain treated with duloxetine showed a greater improve-
ment in BPI-SF average pain score and in MADRS score
compared to patients treated with placebo.9 Interesting-
ly, in this patient population, additional self-rated psy-
chopathological domains assessed with the SCL-90-R
improved over time. For obsessive-compulsive symptom-
atology, interpersonal sensitivity, depressive symptom-
atology, phobic anxiety, and paranoid ideation, the im-
provement was more pronounced in patients taking
duloxetine than in patients taking placebo. Moreover, an
interaction effect between duration of treatment and treat-
ment group was found for obsessive-compulsive symp-
tomatology, depressive symptomatology, somatization,
and anxiety, which suggests that, with increasing duration
of treatment, the improvement in duloxetine-treated pa-
tients became progressively more pronounced than in pa-
tients treated with placebo. This finding also suggests
that, in pain-enriched MDD patients, a treatment (dulox-
etine or placebo) results in an improvement of several
other psychopathological domains and that, for some of
these domains, the effect is more pronounced with dulox-
etine than with placebo. It has been well documented that
antidepressants are indeed also effective in anxiety dis-
orders including obsessive-compulsive disorder. Dulox-
etine has been shown to be effective in subthreshold anx-
ious symptoms in patients with MDD,17,18 but less has
been reported on the other psychopathological domains
Table 5. Regression Analyses of Symptom Clusters Predicting
Improvement as Assessed by the Physicians Versus Patients
at Week 8
Predictor of Improvement t Values p Valuesa
CGI-I (physician) predicted byb
Decrease on MADRS 14.61 < .0001
Younger age –3.51 = .0005
Decrease in SCL-90-R interpersonal sensitivity 2.11 = .0359
PGI-I (patient) predicted byc
Decrease in SCL-90-R depression severity 6.22 < .0001
Decrease in BPI-SF average pain 3.66 = .0003
Decrease in SCL-90-R anxiety 2.89 = .0041
aOnly p values that are significant at ≤ .05 are listed.
bCovariates included in the model were the change from baseline to
week 8 in number of pains, BPI-SF average pain, MADRS total
score, BPI-SF interference (all items), and SCL-90-R (all items);
gender; and age.
cThe decrease on MADRS was not considered as a covariate in this
regression analysis. Covariates included in the model were the
change from baseline to week 8 in number of pains, BPI-SF average
pain, BPI-SF interference (all items), and SCL-90-R (all items);
gender; and age.
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form,
CGI-I = Clinical Global Impressions-Improvement scale,
MADRS = Montgomery-Asberg Depression Rating Scale,
PGI-I = Patient Global Impression of Improvement,
SCL-90-R = Symptom Checklist-90-Revised.
Table 6. Factors Predicting the Discrepancya of
Patient-Assessed Disease Outcome (PGI-I) Versus
Physician-Assessed Disease Outcome (CGI-I) at Week 8b
Predictor of Discrepancy t Values p Values
Low discrepancy between CGI-I and PGI-I
Low decrease in MADRS depression severity –5.68 < .0001
Low decrease in BPI-SF pain interference –2.57 = .0106
with other people
Low decrease in SCL-90-R –2.49 = .0135
interpersonal sensitivity
High discrepancy between CGI-I and PGI-I
Low decrease in BPI-SF average pain 2.37 = .0186
Low decrease in SCL-90-R 3.55 = .0005
patient-rated depression
aDiscrepancy is defined as PGI-I score minus CGI-I score at week 8.
bCovariates included in the regression were the change from baseline
to week 8 in number of pains, BPI-SF average pain, MADRS total
score, BPI-SF interference (all items), and SCL-90-R (all items);
gender; and age.
Abbreviations: BPI-SF = Brief Pain Inventory-Short Form,
CGI-I = Clinical Global Impressions-Improvement scale,
MADRS = Montgomery-Asberg Depression Rating Scale,
PGI-I = Patient Global Impression of Improvement,
SCL-90-R = Symptom Checklist-90-Revised.
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including interpersonal sensitivity, phobic anxiety, para-
noid ideation, and somatization.
Two comments can be made on the basis of the present
findings. First, the findings illustrate an often forgotten
characteristic of the DSM classification system: in DSM-
IV, there is no assumption that each category of mental
disorder is a completely discrete entity with absolute
boundaries dividing it from other mental disorders or
from no mental disorder. This outlook emphasizes the
need to capture additional clinical information that goes
beyond diagnosis, although dimensional systems com-
municate more clinical information because they report
clinical attributes that might be subthreshold.10 Of course,
a halo effect cannot be excluded since it could well be
that depressed patients are so biased by their depressive
mood that they tend to report negative feelings and
symptoms.
Second, the data fit with the belief that antidepressants
are broad spectrum antinervousness compounds since
many are effective in comorbid conditions ranging from
obsessive-compulsive disorders to premenstrual dyspho-
ric disorder.19
The different regression analyses that were run in
order to investigate the associations of the different SCL-
90-R domains with observer-rated depression severity,
self-rated depression severity, as well as with pain sever-
ity and pain interference, revealed clinically relevant in-
formation. Overall, the different self-rated psychopatho-
logical domains of the SCL-90-R were much more
correlated with the self-rated depression severity than
with the observer-rated depression severity. BPI-SF aver-
age pain, obsessive-compulsive symptomatology, inter-
personal sensitivity, and anxiety scores all predicted
higher self-rated depression severity, suggesting that they
are all closely related. The more externally-oriented psy-
chopathological domains (phobic anxiety and paranoid
ideation) both predicted the lower internally oriented do-
main of self-rated depression severity. BPI-SF average
pain severity and interference of pain with functioning
also were more positively predicted by self-rated depres-
sion severity, anxiety, and the somatization subscale,
while also being more negatively predicted by interper-
sonal sensitivity, phobic anxiety, and paranoid ideation.
Additionally, female gender predicted a greater BPI-SF
average pain severity and a more pronounced interfer-
ence of pain with functioning.
The discrepancy between the physician’s and the
patient’s global impressions of improvement was also in-
vestigated. While concordance was found in about half of
the patients, overestimation of improvement by the physi-
cian or underestimation of improvement by the patient
was found in 35% of the enrolled patients. That this
discrepancy was not significantly different in patients
treated with duloxetine compared with patients treated
with placebo suggests that the discrepancy is not due to
the burden of adverse events (higher in duloxetine pa-
tients), as it is sometimes felt that the “clinical global
impression” is a more global measure taking clinical im-
provement and tolerability into account. Indeed, it has
been reported earlier that side effects only marginally af-
fect the “clinical global impression.”3
It is remarkable that, to the extent that societal and
health economic imperatives invite a greater reliance on
self-reported data, the discrepancies between observer-
and self-rated depression severity have not been investi-
gated more thoroughly. Underreporting of depression se-
verity has been suggested in patients with less formal
education and in older patients.20 Overreporting of depres-
sion has been suggested in patients with higher scores
on neuroticism and on oral and hysterical personality
style; underreporting was found in patients with higher
obsessiveness.21,22
The present investigation sheds some new light on
these discrepancies: when assessing global improvement,
doctors seem to take into account mainly the decrease
in observer-rated depression severity (MADRS), interper-
sonal sensitivity, and age, while patients take into account
the change in depressive, anxious, and painful symptom-
atology. This result could well be in line with the finding
that depressive disorders as well as anxiety disorders are
closely related to chronic painful physical symptoms6,7 and
that the presence of (painful) somatic symptoms can result
in underrecognition and underdiagnosis of mental disor-
ders since doctors do not systematically check the differ-
ent symptom clusters but tend to rely on the most obvious
one.23 The data also suggest that physicians make a (DSM-
IV) diagnosis on the basis of many symptoms a patient
first presents; from there onwards, however, they mainly
focus on the symptoms of the “main diagnosis” to assess
improvement. Patients, on the other hand, think less in
terms of “main diagnosis” and take into account the differ-
ent concurrent symptom clusters (depressive, anxious, and
[painful] somatic) when they have to assess improvement.
The limitations of this study include the fact that the
data were calculated post hoc and not prespecified in the
protocol of the study from which the data were derived.
Physicians were asked to rate the diagnosis on the basis of
the MADRS and not on the basis of other scales, suggest-
ing the lack of a thorough diagnosis of depression. There
also may be bias based on the fact that physicians were
asked to follow the protocol per study visit only to avoid
pseudo-behavioral-therapy–like effects with long and ex-
tensive study visits.
CONCLUSIONS
In patients with MDD associated with moderate pain,
physicians consider mainly the change in depressive
symptoms as measured by MADRS in their CGI-I assess-
ment, while patients also consider pain, depression, and
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anxiety in their PGI-I assessment. Making a main diag-
nosis of a MDD should not prevent physicians from tak-
ing into account often concurrent symptomatology such
as anxious and painful physical symptoms.
Drug name: duloxetine (Cymbalta).
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